复方苦参注射液对小鼠肝癌H22细胞增殖的影响  

Effects of Compound Kushen Injection on proliferation of hepatocellular cancer H22 cells

作　　者：刘清 阳卫立 王伟 海丽娜 罗永胜 胡双成 LIU Zhi-zhong LIU Qing;YANG Wei-li;LIU Zhi-zhong;WANG Wei;LUO Yong-sheng;HU Shuang-cheng(Department of Gastroenterology, Second people’s Hospital ofFutian District, Shenzhen 518049,China;The second People’sHospital of Zhuhai, Zhuhai 519000,China;Academy for Advanced Interdisciplinary Studies,Peking University,Beijing100871,China)

机构地区：[1]深圳市福田区第二人民医院消化内科 [2]珠海市第二人民医院 [3]北京大学前沿交叉学科研究院

出　　处：《现代消化及介入诊疗》2019年第5期482-485,共4页Modern Interventional Diagnosis and Treatment in Gastroenterology

基　　金：广东省中医药局科研课题(20142137,20151092);福田区卫生公益性科研项目(FTWS2015004)

摘　　要：目的 研究复方苦参注射液抑制小鼠肝癌细胞H22增殖的作用,为复方苦参注射液用于肝癌治疗提供依据。方法 采用小鼠H22肝癌模型进行复方苦参注射液的体内抑瘤实验,测定肿瘤生长抑制率(IR),对小鼠右腋皮下接种肝癌H22实体瘤(腹水转实体),复方苦参注射液35、30、15、7.5、3.75g生药/kg对小鼠腹腔注射给药,1次/d,连续12d;观察抑瘤作用,按照复方苦参注射液30、15、7.5、3.75、1.88g生药/kg,1次/d,连续12d,对已接种肝癌H22实体瘤的小鼠腹腔注射给药,自给药后第一天起,连续45d记录观察小鼠的死亡情况。结果 复方苦参注射液的各剂量组均可明显抑制小鼠肝癌H22移植性肿瘤瘤重(与模型对照组比较P<50.05),抑瘤率在39.63%~56.71%,且复方苦参注射液对肝腹水癌小鼠的存活天数有明显的延长作用,生命延长率可达57.71~86.28%。结论 复方苦参注射液对小鼠肝癌H22移植性肿瘤具有明显的抑制作用,抑制小鼠肝癌细胞H22增殖并能显著延长小鼠的生存期,且呈现出明显的浓度依赖性。Objective To study the inhibitory effect of Compound Kushen Injection on the proliferation of hepatocellular carcinoma cell H22, and provide evidence for the treatment of hepatocellular carcinoma. Methods The tumor inhibition experiment of compound kushen injection in vivo was carried out using mouse H22 hepatocellular carcinoma mouse model to measure the inhibition rate (IR) of tumor growth. The mice were subcutaneously inoculated with hepatoma H22 and intraperitoneally injected with 35, 30,15, 7.5 and 3.75 g Compound Kushen Injection once a day for12 days consecutive to observe the anti-tumor effect. The mice, inoculated with hepatoma H22, were intraperitoneally injected with 35, 30,15, 7.5 and 3.75 g Compound Kushen Injection once a day for12 days. From the first day after injecting, the mortality of mice was recorded for 45 days. Results The all dose groups of Compound Kushen Injection could significantly inhibit the weight of mice hepatocellular carcinoma H22 ( P <0.05 or P <0.01 compared with control group), the IR was 39.63~56.71%. The Compound Kushen Injection also could significantly prolong the survival days of mice with hepatocellular carcinoma H22, and the prolongation rate was 57.71~86.28%. Conclusion The Compound Kushen Injection can effectively inhibit the proliferation of H22 hepatoma in mice and prolong the survival time of mice with a concentration-dependent manner.

关 键 词：复方苦参注射液 肝癌H22 增殖抑制 

分 类 号：R574[医药卫生—消化系统]